Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PIII
PIII logo

PIII Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
14.320
Open
14.270
VWAP
12.99
Vol
231.42K
Mkt Cap
91.20M
Low
12.270
Amount
3.01M
EV/EBITDA(TTM)
--
Total Shares
--
EV
234.88M
EV/OCF(TTM)
--
P/S(TTM)
0.01
P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.
Show More

Events Timeline

(ET)
2026-05-19
10:00:00
P3 Health Partners Inc Trading Resumes
select
2026-05-19
09:50:00
P3 Health Partners Inc Trading Halted Due to Volatility
select
2026-05-14 (ET)
2026-05-14
16:20:00
Sees FY26 Adjusted EBITDA of $20M-$60M
select
2026-05-14
16:20:00
P3 Reports Q1 Revenue of $386M, Raises 2026 Adjusted EBITDA Outlook to $40M
select
2026-04-29 (ET)
2026-04-29
11:20:00
P3 Health Partners Enters Debt Exchange Agreement with Chicago Pacific Founders
select
link
2026-03-27 (ET)
2026-03-27
09:00:00
Stock Futures Modestly Lower as Energy Prices Rise
select

News

NASDAQ.COM
2.0
05-22NASDAQ.COM
Multiple Companies Experience Significant Stock Price Gains
  • CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
  • AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
  • P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
  • Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
seekingalpha
9.5
05-15seekingalpha
P3 Health Partners Reports Strong Q1 2026 Earnings and Raises Outlook
  • Strong Financial Performance: P3 Health Partners reported $26 million in adjusted EBITDA for Q1 2026, exceeding internal expectations, which reflects the company's success in contract restructuring and market optimization, thereby enhancing confidence in its full-year outlook.
  • Strategic Market Adjustments: CEO Aric Coffman emphasized a 15% year-over-year improvement in Medicare Advantage funding rates, with 63% of membership experiencing delegated functions, indicating a strategic shift in prioritizing markets and payer relationships.
  • Revenue and Cost Control: Q1 revenue reached $386 million, up from $373 million in Q1 2025, despite a decline in membership to approximately 106,000, reflecting deliberate portfolio adjustments under economic thresholds.
  • Optimistic Outlook: CFO Leif Pedersen revised the 2026 adjusted EBITDA outlook to a range of $20 million to $60 million, highlighting that this change reflects favorable prior year developments and payer settlements, showcasing the company's confidence in its operational trajectory moving forward.
seekingalpha
9.5
05-14seekingalpha
P3 Health Partners Q1 Earnings Beat Expectations
  • Earnings Beat: P3 Health Partners reported a Q1 GAAP EPS of $0.32, surpassing expectations by $3.60, indicating strong profitability despite revenue falling short of forecasts.
  • Slow Revenue Growth: The company generated $386 million in revenue for Q1, reflecting a 3.4% year-over-year increase, yet it missed analyst expectations by $5.5 million, which could undermine investor confidence in future growth.
  • Market Reaction Analysis: While the earnings beat may initially support stock performance, the revenue miss could lead to volatility, prompting investors to closely monitor the company's strategic adjustments and market performance for long-term investment assessments.
  • Future Outlook: The company must implement strategies to enhance revenue growth to meet market competition and investor expectations, ensuring a more comprehensive performance improvement in upcoming earnings reports.
seekingalpha
9.5
03-26seekingalpha
P3 Health Partners Q4 Earnings Report Analysis
  • Earnings Performance: P3 Health Partners reported a Q4 GAAP EPS of -$23.02, missing expectations by $13.56, indicating ongoing challenges in profitability that may negatively impact investor confidence.
  • Revenue Surge: The company achieved Q4 revenue of $384.8M, a staggering 1153.4% increase year-over-year, exceeding expectations by $27.15M, demonstrating strong market demand despite a slight decline from last year's $1.50B total revenue.
  • Medical Margin Improvement: The medical margin stood at $23.5M, or $17 PMPM, with normalized medical margin at $53.4M, reflecting progress in cost control and service efficiency, although the net loss reached $323.1M.
  • Future Guidance: For 2026, adjusted EBITDA is expected to range from -$20M to $40M, with a midpoint of $10M, indicating a projected year-over-year improvement of approximately $170M, showcasing management's confidence in future profitability.
moomoo
7.0
03-26moomoo
P3 Health Partners Inc. Projects Total Revenue Between $1.5 Billion and $1.7 Billion for 2026
  • Revenue Guidance: Health Partners Inc. has provided a total revenue guidance range for 2026, estimating between $1.5 billion and $1.7 billion.
moomoo
9.5
03-26moomoo
P3 Health Partners Reports Results for Fourth Quarter and Full Year 2025
  • Fourth Quarter Results: Health Partners has announced its results for the fourth quarter of 2025, highlighting key financial and operational metrics.

  • Full Year Performance: The organization also provided a comprehensive overview of its performance for the entire year of 2025, showcasing growth and achievements.

Wall Street analysts forecast PIII stock price to rise
4 Analyst Rating
Wall Street analysts forecast PIII stock price to rise
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
8.00
Averages
14.00
High
20.00
Current: 0.000
sliders
Low
8.00
Averages
14.00
High
20.00
Lake Street
NULL
to
Buy
upgrade
$4 -> $14
AI Analysis
2026-05-15
Reason
Lake Street
Price Target
$4 -> $14
AI Analysis
2026-05-15
upgrade
NULL
to
Buy
Reason
Lake Street raised the firm's price target on P3 Health Partners to $14 from $4 and keeps a Buy rating on the shares. The transitional year of 2025 is "finally over" and 2026 is "off to an auspicious start" with the conversion of debt to equity and a shored-up balance sheet, the analyst tells investors. While it may take a couple more quarters for sentiment to fully shift, the firm thinks "the possibility for substantial upside and meaningful multiple expansion is more assured today than it has been in years," the analyst added.
TD Cowen
Gary Taylor
Hold
downgrade
$6 -> $3
2026-04-02
Reason
TD Cowen
Gary Taylor
Price Target
$6 -> $3
2026-04-02
downgrade
Hold
Reason
TD Cowen analyst Gary Taylor lowered the firm's price target on P3 Health Partners to $3 from $6 and keeps a Hold rating on the shares. The firm updated its model following Q3 results and said its target reflects reflects 0.2x its 2027 revenue estimates.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PIII
Unlock Now

Valuation Metrics

The current forward P/E ratio for P3 Health Partners Inc (PIII.O) is -0.33, compared to its 5-year average forward P/E of -5.45. For a more detailed relative valuation and DCF analysis to assess P3 Health Partners Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.45
Current PE
-0.33
Overvalued PE
3.49
Undervalued PE
-14.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.42
Current EV/EBITDA
-6.08
Overvalued EV/EBITDA
85.46
Undervalued EV/EBITDA
-90.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.17
Current PS
0.02
Overvalued PS
0.34
Undervalued PS
0.01

Financials

AI Analysis
Annual
Quarterly

Whales Holding PIII

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is P3 Health Partners Inc (PIII) stock price today?

The current price of PIII is 12.382 USD — it has decreased -6.2

What is P3 Health Partners Inc (PIII)'s business?

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.

What is the price predicton of PIII Stock?

Wall Street analysts forecast PIII stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PIII is14.00 USD with a low forecast of 8.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is P3 Health Partners Inc (PIII)'s revenue for the last quarter?

P3 Health Partners Inc revenue for the last quarter amounts to 373.23M USD, decreased -3.93

What is P3 Health Partners Inc (PIII)'s earnings per share (EPS) for the last quarter?

P3 Health Partners Inc. EPS for the last quarter amounts to -314.11 USD, increased 3896.31

How many employees does P3 Health Partners Inc (PIII). have?

P3 Health Partners Inc (PIII) has 360 emplpoyees as of May 26 2026.

What is P3 Health Partners Inc (PIII) market cap?

Today PIII has the market capitalization of 91.20M USD.